
|Videos|June 3, 2018
Promising Results for Pembrolizumab With Bevacizumab in mRCC
Author(s)Shilpa Gupta, MD
Shilpa Gupta, MD, assistant professor of Medicine in the Hematology, Oncology, and Transplantation Division, University of Minnesota, discusses phase Ib and phase II studies of pembrolizumab (Keytruda) with bevacizumab (Avastin) for the treatment of metastatic renal cell carcinoma during the 2018 ASCO Annual Meeting.
Advertisement
Shilpa Gupta, MD, assistant professor of Medicine in the Hematology, Oncology, and Transplantation Division, University of Minnesota, discusses phase Ib and phase II studies of pembrolizumab (Keytruda) with bevacizumab (Avastin) for the treatment of metastatic renal cell carcinoma (mRCC) during the 2018 ASCO Annual Meeting.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Panel Votes 10-3 In Favor of RP1 Plus Nivolumab for Advanced Melanoma
2
Improving Survival, Quality of Life, and Cost-Effectiveness for Allo-HCT
3
FDA Grants Priority Review to Subcutaneous Amivantamab for Advanced HNSCC
4
NCCN Lists Gedatolisib Regimens as Preferred Option in HR+/HER2– Metastatic Breast Cancer
5




































